Mecanismos de acción de péptidos antimicrobianos Ib-M contra Escherichia coli. Un estudio estructural y proteómico

Authors

  • Ana Elvira Farfán García Universidad de Antioquia, Universidad de Santander
  • Eliana Durley Restrepo Pineda Universidad de Antioquia
  • Johanna Marcela Flórez-Castillo Universidad de Santander

DOI:

https://doi.org/10.17533/udea.iatreia.342220

Keywords:

péptidos, antibacterianos, Escherichia coli, relación estructura-actividad, membrana celular
|Abstract
= 259 veces | PDF (ESPAÑOL (ESPAÑA))
= 0 veces|

Downloads

Download data is not yet available.

Author Biographies

Ana Elvira Farfán García, Universidad de Antioquia, Universidad de Santander

Doctorado Ciencias Básicas Biomédicas. Corporación de Ciencias Básicas Biomédicas, Universidad de Antioquia. Investigador Grupo de Investigación en Manejo Clínico –CliniUDES, Universidad de Santander.

Eliana Durley Restrepo Pineda, Universidad de Antioquia

Doctora en Ciencias Básicas Biomédicas. Corporación de Ciencias Básicas Biomédicas, Grupo Bacterias y Cáncer. 

Johanna Marcela Flórez-Castillo, Universidad de Santander

Departamento de Ciencias Exactas, Exactas, Naturales y Agropecuarias. Grupo de Investigación en Ciencias Básicas y Aplicadas –CIBAS–, Universidad de Santander.

References

(1) Arias M, Jensen KV, Nguyen LT, Storey DG, Vogel HJ. Hydroxy-tryptophan containing derivatives of tritrpticin:

modification of antimicrobial activity and membrane interactions. Biochim Biophys Acta. 2015;1848(1 Pt B):277-288.

(2) Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis. 2001;1(3):156-64.

(3) Scott MG, Hancock RE. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol. 2000;20(5):407-31.

(4) Ashby M, Petkova A, Hilpert K. Cationic antimicrobial peptides as potential new therapeutic agents in neonates and children: a review. Curr Opin Infect Dis. 2014;27(3):258-267.

(5) Giuliani A, Pirri G, Nicoletto GF. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol. 2007;2(1):1-33.

(6) Miao J, Chen F, Duan S, Gao X, Liu G, Chen Y, et al. iTRAQ-Based Quantitative Proteomic Analysis of the Antimicrobial Mechanism of Peptide F1 against Escherichia coli. J Agric Food Chem. 2015;63(32):7190-7197.

(7) Kozlowska J, Vermeer LS, Rogers GB, Rehnnuma N, Amos TA, Koller G, et al. Combined systems approaches reveal highly plastic responses to antimicrobial peptide challenge in Escherichia coli. PLoS Pathog. 2014;10(5):e1004104.

(8) Sinha S, Zheng L, Mu Y, Ng WJ, Bhattacharjya S. Structure and Interactions of A Host Defense Antimicrobial Peptide Thanatin in Lipopolysaccharide Micelles Reveal Mechanism of Bacterial Cell Agglutination. Sci Rep. 2017;7(1):17795.

(9) Arias M, Hoffarth ER, Ishida H, Aramini JM, Vogel HJ. Recombinant expression, antimicrobial activity and mechanism of action of tritrpticin analogs containing fluoro-tryptophan residues. Biochim Biophys Acta. 2016;1858(5):1012-1023.

(10) Liu B, Huang H, Yang Z, Liu B, Gou S, Zhong C, et al. Design of novel antimicrobial peptide dimer analogues

with enhanced antimicrobial activity in vitro and in vivo by intermolecular triazole bridge strategy. Peptides. 2017;88:115-125.

(11) Flórez-Castillo JM, Perullini M, Jobbágy M, Cano Calle HJ, International Journal of Peptide Research and Therapeutics. Enhancing Antibacterial Activity Against Escherichia coli K-12 of Peptide Ib-AMP4 with Synthetic Analogues. Int J Pept Res Ther. 2014;20(3):365–369.

Published

2020-07-30

How to Cite

1.
Farfán García AE, Restrepo Pineda ED, Flórez-Castillo JM. Mecanismos de acción de péptidos antimicrobianos Ib-M contra Escherichia coli. Un estudio estructural y proteómico. Iatreia [Internet]. 2020 Jul. 30 [cited 2026 Mar. 2];33(1-S):S39-S40. Available from: https://revistas.udea.edu.co/index.php/iatreia/article/view/342220

Issue

Section

Supplement

Similar Articles

You may also start an advanced similarity search for this article.